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ifosfamide, and trofosfamide, constitute a class of alkylating agents that have a broad spectrum of
anticancer activity against many malignant ailments including both solid tumors such as breast
cancer and hematological malignancies such as leukemia and lymphoma. Most oxazaphosphorines
are prodrugs that require hepatic cytochrome P450 enzymes to generate active alkylating moieties
before manifesting their chemotherapeutic effects. Meanwhile, oxazaphosphorines can also be
transformed into non-therapeutic byproducts by various drug-metabolizing enzymes. Clinically,
oxazaphosphorines are often administered in combination with other chemotherapeutics in
adjuvant treatments. As such, the therapeutic efﬁcacy, off-target toxicity, and unintentional
drug–drug interactions of oxazaphosphorines have been long-lasting clinical concerns and
heightened focuses of scientiﬁc literatures. Recent evidence suggests that xenobiotic receptors
may play important roles in regulating the metabolism and clearance of oxazaphosphorines. Drugs
as modulators of xenobiotic receptors can affect the therapeutic efﬁcacy, cytotoxicity, and
pharmacokinetics of coadministered oxazaphosphorines, providing a new molecular mechanism
of drug–drug interactions. Here, we review current advances regarding the inﬂuence of xenobioticedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
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Duan Wang, Hongbing Wang108receptors, particularly, the constitutive androstane receptor, the pregnane X receptor and the aryl
hydrocarbon receptor, on the bioactivation and detoxiﬁcation of oxazaphosphorines, with a focus
on cyclophosphamide and ifosfamide.
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Oxazaphosphorines are a class of bi-functional alkylating
agents that have been extensively investigated in the past 50
years for their anticancer and immune-regulating activities,
with the most successful representatives including cyclopho-
sphamide (CPA), ifosfamide (IFO), and to a lesser extent
trofosfamide1–4. Most oxazaphosphorines are designed pro-
drugs, which require cytochrome P450 (CYP) enzyme-
mediated bioactivation to generate highly reactive alkylating
nitrogen mustards that exert their chemotherapeutic effects by
attacking speciﬁc nucleophilic groups of DNA molecules in
target cancer cells5–10. CPA is the ﬁrst oxazaphosphorine
agent that achieved great success in its clinical application in
many cancer patients11–13. Although CPA has been clinically
available for over a half century, it continues to be amongst
the front-line choices of chemotherapy for solid tumors,
such as breast cancer, for which it is used as an important
component of the CPA-methotrexate-ﬂuorouracil (CMF) regi-
men14,15, and hematopoietic malignancies, such as non-Hodg-
kin lymphoma, for which it is applied as a critical constituent
of the rituximab–CPA–doxorubicin–vincristine–prednisone
(R-CHOP) multidrug regimen16,17. Additionally, CPA has
also been used at higher doses in the treatment of aplastic
anemia and leukemia prior to bone marrow transplantation
and as a therapeutic immunosuppressor for several autoim-
mune disorders18,19.
IFO, the second anticancer drug in the oxazaphosphorine
class, was introduced to clinics in the early 19704,20. Developed
as an analog of CPA, IFO only differs chemically from CPA
by one chloroethyl group transpositioned from the mustard
nitrogen to the ring nitrogen21. Like CPA, IFO also requires
CYP-mediated metabolism to produce active alkylating moi-
eties before manifesting its antitumor effects22,23. Clinically,
IFO has been used in young adult and pediatric tumors along
with other chemotherapeutics in adjuvant treatment. In a
number of malignant diseases, IFO exhibits a higher ther-
apeutic response rate, with less myelosuppression, in compar-
ison with its parent analog CPA24,25. Trofosfamide is another
derivative of CPA and an orally administered oxazapho-
sphorine prodrug with high bioavailability26. As a congener
of CPA and IFO, the antitumor cytotoxicity of trofosfamide
also relies on its metabolic activation by ‘‘ring’’ oxidation,
using the hepatic mixed-function oxidase system27,28. Trofos-
famide is often used clinically in adult soft tissue sarcomas
and non-Hodgkin lymphomas with relatively low toxicity
proﬁles29–31.
In addition to these traditional oxazaphosphorines, several
new analogs of CPA and IFO such as mafosfamide and glufos-
famide have been designed, aiming to achieve increased therapeu-
tic selectivity and reduced off-target toxicity, in comparison
with their ascendants32,33. Unlike traditional oxazaphosphorines,mafosfamide and glufosfamide do not require hepatic oxidative
enzyme-mediated bioactivation. For instance, mafosfamide is a
4-thioethane sulfonic acid salt of 4-hydroxycyclophosphamide (4-
OH–CPA), a key bioactive intermediate metabolite of CPA10,34;
while glufosfamide is a glucose conjugate of ifosfamide, in
which isophosphoramide mustard, the bioactive alkylating
metabolite of ifosfamide, is covalently linked to b-D-glu-
cose35,36. At present, several Phase I studies have shown
favorable outcomes from intrathecal administration of mafos-
famide in the treatment of meningeal malignancies, although
further comprehensive clinical evaluation is needed37,38. In
the case of glufosfamide, the development of this oxazapho-
sphorine agent was based on the rationale that cancer cells are
active in importing and utilizing glucose. Thus, the differential
expression of transmembrane glucose transporters between
cancer and normal cells accounts for the target selectivity
of glufosfamide39,40. Recent clinical trials revealed beneﬁcial
effects of utilizing glufosfamide in the treatment of pancreatic
adenocarcinoma, non-small cell lung cancer, as well as head
and neck squamous cell carcinoma41–43. Together, these promis-
ing anticancer activities of mafosfamide and glufosfamide indi-
cate that new generation of oxazaphosphorine agents, with better
target selectivity and less unwanted cytotoxicity, could be
clinically available in the near future.
The journey of our understanding of the mechanisms
underlying oxazaphosphorine action started with the develop-
ment of CPA. After many years of intensive investigation,
although a number of new oxazaphosphorine derivatives
displayed promising therapeutic features, currently, CPA and
IFO remain to be the most successful and widely used
oxazaphosphorines in the treatment of an array of various
malignancies. As aforementioned, CPA and IFO are prodrugs
requiring metabolic activation by hepatic drug-metabolizing
enzymes. The expression and functional perturbation of these
enzymes can dramatically inﬂuence the metabolism, clearance,
and pharmacokinetics of these oxazaphosphorines. Recently,
accumulating evidence suggests that nuclear receptors, in
particular, a group of so-called ‘‘xenobiotic receptors’’, are
the primary regulators governing the transcription of most
hepatic drug-metabolizing enzymes and drug transporters44–46.
Drugs as modulators of xenobiotic receptors can affect the
metabolism rate and pharmacokinetics of coadministered
oxazaphosphorines, and dictate their therapeutic efﬁcacy and
toxicity, accordingly. The current review tends to highlight the
recent advances in elucidating the roles of xenobiotic receptors
in mediating the bioactivation and deactivation of oxazapho-
sphorines with the focus on the roles of the constitutive
androstane receptor (CAR, NR1I3), the pregnane X receptor
(PXR, NR1I2), and the Aryl hydrocarbon receptor (AhR) on
metabolism and clearance of CPA and IFO. This review
however is by no means a comprehensive coverage of all
ﬁndings of oxazaphosphorine research.
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2.1. Cytochrome P450
Prototypical oxazaphosphorine cytostatics such as CPA and
IFO are chemically and pharmacologically inactive transport
forms of alkylating nitrogen mustards that are biotransformed
to their active forms predominantly in the liver47,48. As one of
the key mechanisms of action, hepatic metabolism of CPA,
has been extensively studied during the past several decades,
utilizing human and animal liver microsomes, primary hepa-
tocytes, recombinant CYP enzymes, CYP-selective chemical
and antibody inhibitors, as well as whole animal models48–50.
Upon administration, CPA undergoes hepatic oxidation to
form the pharmacologically active intermediate metabolite
4-OH-CPA, which enters blood circulation and is transported
to target tissues by binding to erythrocytes51–54. 4-OH-CPA is
further tautomerized to aldophosphamide, followed by spon-
taneous b-elimination to release the phosphoramide mustard
as the ﬁnal DNA-cross-linking metabolite10,55. Notably,
hydroxylation of CPA at the 4-carbon position is the rate
limiting step of its bioactivation, and blood concentration of
4-OH-CPA has often been used as a biomarker monitoring the
efﬁcacy of CPA therapeutics56–58. Multiple CYP isozymes are
involved in the hydroxylation of CPA, including CYP2A6,
CYP2B6, CYP3A4, CYP3A5, CYP2C9, CYP2C18, and
CYP2C1949,50,59,60, with CYP2B6 being the primary player,
which contributes approximately 45% of CPA bioactiva-
tion48–50. To a lesser extent, CYP3A4 and CYP2C9 also
contribute around 25% and 12% of CPA 4-hydroxylation,
respectively49,50. Alternatively, CPA is subject to signiﬁcant
side-chain oxidation, primarily N-dechloroethylation, by a
number of CYPs to generate the inactive dechloroethyl-CPA
and the toxic byproduct chloroacetaldehyde (CAA)27,49,58,60
(Fig. 1). The predominant CYP enzyme responsible for the N-
dechloroethylation of CPA is CYP3A4, which was reported toFigure 1 Schematic summary of cyclophosphamide (CPA) and if
biotransformed through a group of CYP and non-CYP drug-metaboliz
mustards, as well as non-therapeutic metabolic byproducts (modiﬁedbe responsible for up to 95% of this reaction, followed by
CYP3A7 and CYP3A527,49,53,60. On the other hand, CYP2B6
only provides negligible contribution to this non-therapeutic
biotransformation of CPA60.
Metabolism of IFO shares a generally CYP-based pathway
in common with that of CPA, but exhibits differential CYP
afﬁnity and metabolism rates23,34. Akin to CPA, IFO is
bioactivated by CYP3A4 and CYP2B6 to form the 4-
hydroxy-ifosfamide (4-OH-IFO), which subsequently goes
through a series of biochemical reactions to yield the ultimate
therapeutic alkylating agent, ifosfamide mustard48,61. More
detailed characterization, however, revealed that CYP3A4
plays a major role in the 4-hydroxylation of IFO with
CYP2B6 as a supplementary isozyme56,62. Moreover, these
two CYP enzymes also control the N-dechloroethylation of
IFO forming the neurotoxic CAA49,60 , with CYP3A4 con-
tributing approximately 70% of liver microsomal CAA for-
mation and CYP2B6 accounting for roughly 25%34,49.
Additionally, CYP3A5 was also reported to be involved in
the dechloroethylation of IFO. Polymorphic mutations of
CYP3A5 can affect the rate of CAA formation as well63.
In comparing the biotransformation of CPA and IFO, only
10% of CPA is subject to N-dechloroethylation, whereas
approximately 25–60% of IFO undergo this metabolic path-
way, generating more toxic byproducts58,64,65. This rather
distinct proﬁle of metabolism also contributes to the clinically
observed side-effect, in which CAA-mediated neurotoxicity
occurs in 20% of IFO-treated patients, while happens quite
rare in CPA-treated patients66,67. Importantly, CYP enzymes
are involved differentially in the biotransformation of these
oxazaphosphorines; for instance, CYP2B6 selectively activates
CPA over IFO and only exhibits a negligible effect on CPA-N-
dechloroethylation. Therefore, it might be possible to design
novel CPA-based therapeutic regimens by modulating these
metabolic pathways to achieve greater bioactivation without
concurrent augmentation of unwanted cytotoxicity.osfamide (IFO) metabolism. The prodrugs CPA and IFO are
ing enzymes to form their therapeutically active DNA-crosslinking
from Wang et al.120).
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Following CYP-mediated 4-hydroxylation, both CPA and IFO
can be further activated to their corresponding therapeutic
mustards or inactivated to different byproducts through sequen-
tial metabolic processes mediated by other non-CYP drug-
metabolizing enzymes26,34. First, 4-OH-CPA quickly reaches
equilibrium with its acyclic form, aldophosphamide, which can
be spontaneously decomposed through b-elimination to form the
ultimate active alkylating product phosphoramide mustard and a
urotoxic byproduct acrolein, which is commonly associated with
clinically important hemorrhagic cystitis3,10,34. Intracellular phos-
phoramide mustard then attacks host DNA to exert expected
cytotoxicity. Alternatively, phosphoramide mustard can undergo
detoxiﬁcation by glutathione S-transferase (GST)-mediated con-
jugation, hydrolysis of the chloroethyl side chain to form
alcohols, or cleavage of the phosphorus-nitrogen bond to release
3-(2-chloroethyl)-1,3-oxazolidin-2-one (CNM), which are all
metabolic byproducts without antitumor activity68. The acrolein,
meanwhile, is converted to acrylic acid by aldehyde dehydro-
genases (ALDH), ALDH1A1 and ALDH3A169,70. An impor-
tant detoxiﬁcation pathway for 4-OH-CPA is the conversion of
its tautomer, aldophosphamide, to the less toxic carboxypho-
sphamide (CEPM), which represents a major stable non-ther-
apeutic metabolite of CPA found in clinical samples71,72. This
oxidative reaction is primarily catalyzed by ALDH1A173,74 , and
to a lesser extent by ALDH3A1 and ALDH5A175. Alternatively,
aldophosphamide can be oxidized to form alcophosphamide by
alcohol dehydrogenase (ADH) and aldo-keto reductase
(AKR1)76 (Fig. 1). An additional detoxiﬁcation pathway occurs
through reversible dehydration to form imminocyclophospha-
mide, which is further conjugated with glutathione mediated by
GSTA1, GSTA2, GSTM1, and GSTP1, and eventually gener-
ates the nontoxic 4-glutathionylcyclophosphamide77,78.
The major difference regarding the metabolism of CPA and
IFO happens in the CYP-mediated 4-hydroxylation and N-
dechloroethylation. Metabolic destinations of these oxazapho-
sphorines thereafter are highly comparable. As with 4-OH-CPA,
4-OH-IFO exists in equilibrium with its tautomer aldoifosfamide,
which decomposes through b-elimination to yield ifosforamide
mustard and acrolein. Ifosforamide mustard is also subject to
further degradation, forming the inactive metabolite CNM and
chloroethylamine79. Similarly, 4-OH-IFO can also be biotrans-
formed to carboxyifosfamide by ALDH1A1, to 4-keto-IFO by
AKR1, or to alcoifosfamide by ADH and AKR123,34. Glu-
tathione conjugation represents another important detoxiﬁcation
mechanism of ifosforamide mustard80.
Collectively, it is evident now that both CYP and non-CYP
drug-metabolizing enzymes can contribute to the bioactivation
and detoxiﬁcation of CPA and IFO. Although liver contains
the most abundant drug-metabolizing enzymes and plays
predominant roles in the biotransformation of oxazapho-
sphorines, extrahepatic tissue-speciﬁc expression of these
enzymes also contribute to the targeted ‘‘selective cytotoxi-
city’’ which is one of the leading motive in developing safe and
effective chemotherapeutics.
2.3. Drug transporters
It is believed that all oxazaphosphorine prodrugs are highly
hydrophilic and thus are not easily diffused across cell
membranes. Mounting clinical and experimental evidence,however, agreed that both CPA and IFO can be readily
administered orally or intravenously with high bioavailability
and decent intracellular concentrations81–83. These phenomena
suggest that active uptake transporters may contribute to the
absorption of these oxazaphosphorines though direct scientiﬁc
support is limited thus far. Conversely, the circular proactive
metabolites of these oxazaphosphorines, 4-OH-CPA, aldopho-
sphamide and 4-OH-IFO, can easily cross the lipid bilayer
membranes of many cells through passive diffusion34. In
contrast to uptake, more research efforts have been centered
on the efﬂux transportation of these alkylating agents from
cancer cells, which is pivotal in multidrug resistance of cancer
chemotherapy. In this regard, a number of ATP-binding
cassette transporters have been identiﬁed as transmembrane
modulators associated with exporting CPA, IFO, and their
metabolites34,84,85.
In vitro studies, utilizing HepG2 cells stably transfected
with multidrug resistance-associated protein 4 (MRP4, ABCC4)
expression vector, have clearly established that CPA and IFO are
substrates of this efﬂux transporter. Overexpression of MRP4 in
HepG2 cells led to increased resistance to CPA- and IFO-induced
cytotoxicity, while inhibition of this transporter by diclofenac or
celecoxib, two known inhibitors of MRP4, signiﬁcantly sensitized
the MRP4-HepG2 cells to CPA and IFO85,86. Notably, glu-
tathione, the most abundant cellular redox molecule, plays an
important role in the function of MRP4 and depletion of
intracellular glutathione can signiﬁcantly affect the export of
cAMP by MRP487,88. Since glutathione is pivotal in detoxiﬁcation
of phosphamide and ifosforamide mustards, it was speculated that
MRP4-mediated resistance to CPA and IFO might be glu-
tathione-dependent. Indeed, addition of buthionine sulfoximine,
a glutathione synthesis inhibitor, considerably reversed MRP4-
mediated resistance to CPA and IFO in MRP4-HepG2 cells86.
The multidrug resistance-associated protein 2 (MRP2,
ABCC2) has been reported to export a detoxiﬁed CPA
metabolite, 4-glutathionylcyclophosphamide, from hepato-
cytes into the bile in rats; this biliary excretion appears to
compete with the bioactivation pathway that generates the
active alkylating agent89. In addition, clinical studies have
shown that multidrug resistance-associated protein 1 (MRP1,
ABCC1) and the breast cancer resistance protein (BCRP,
ABCG2) are involved in the resistance to chemotherapy in
breast cancer patients receiving CMF regimen90–92. However,
whether CPA and/or its metabolites are substrates of BCRP
and/or MRP1 requires further investigation, given that meth-
otrexate and 5-ﬂuorouracil in the CMF regimen are known
substrates of BCRP93,94.
MRP1, MRP2, and BCRP are all expressed in the apical
(canalicular) membrane of hepatocytes and are in charge of
hepatic biliary excretion of many drugs and endobiotics into
the bile. Conversely, MRP4 is localized in the basolateral
(sinusoidal) membrane of hepatocytes and in the apical
(luminal) membrane of kidney proximal tubules95. The fact
that approximately 70% of CPA is excreted in urine and only
a small portion through the bile, may positively reﬂect the
importance of MRP4 in CPA transportation23,96.3. Xenobiotic receptor and oxazaphosphorine metabolism
It is evident that the oxazaphosphorine type of alkylating
prodrugs require hepatic biotransformation mediated by many
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alkylating mustards, with CYP2B6 and CYP3A4 predomi-
nantly governing the initial and rate-limiting step of their
bioactivation. Although induction of CYP expression gener-
ally increases the elimination of drugs and leads to therapeutic
failure, in the case of CPA and IFO, increasing CYP-mediated
biotransformation can generate more cytotoxic intermediate
metabolites with and without therapeutic potentials, which
may lead to comprehensive prognostic outcomes. Many drugs
and environmental chemicals can inﬂuence the expression of
these CYP enzymes, which are transcriptionally regulated by a
group of transcription factors termed xenobiotic recep-
tors97–100. Unlike traditional endocrine hormone receptors,
xenobiotic receptors, functioning as sensors of toxic bypro-
ducts derived from both endogenous and exogenous chemical
breakdowns, are typically activated by abundant but low-
afﬁnity lipophilic molecules at rather high (micromolar)
concentrations, without real endogenous ligands identiﬁed
thus far101,102. Major xenobiotic receptors, including PXR,
CAR and AhR, predominantly localized in the liver and
intestines, have been documented as important xenobiotic
sensors mediating the transcription of drug-metabolizing
enzymes and transporters associated with the metabolism
and clearance of oxazaphosphorines.3.1. Pregnane X receptor (PXR)
As one of the important components of the body’s adaptive
defense mechanism against xenobiotics, PXR represents the
most promiscuous xenosensor among all xenobiotic receptors
and can be activated by a broad spectrum of ligands including
prescription drugs, herbal medicines, environmental pollu-
tants, and endobiotic derivatives100,103–105. The structural
diversity of PXR ligands stems mainly from the unusually
large, spherical, and ﬂexible ligand binding pocket of the
receptor106,107. Drug-mediated activation of PXR is associated
with the inductive expression of many target genes including
drug-metabolizing enzymes, such as CYP3A4, CYP2B6, CYP2Cs,
and UDP-glucuronosyltransferases (UGT); and drug transpor-
ters, such as the multidrug resistance 1 (MDR1, ABCB1), and
MRPs by recognizing and binding to speciﬁc xenobiotic response
elements located in the promoters of these genes45,103,108. Among
others, CYP3A4 and CYP2B6 are highly inducible PXR target
genes, which exhibit marked inter- and intra-individual variations
in their expression109,110. As such, many clinically used drugs as
PXR activators can inﬂuence the pharmacokinetics of CPA and
IFO when coadministered in multidrug regimens. Additionally,
accumulating evidence suggests that hepatic bioactivation of CPA
and IFO is auto-inducible upon repeated application of these
oxazaphosphorines61,111,112.
Both CPA and IFO have been identiﬁed as human PXR
agonists that contribute signiﬁcantly to the observed auto-
induction of CYP2B6 and CYP3A4 by which their own
metabolism and clearance are increased100,105,113. In this
process, CPA and IFO bind to the ligand binding domain of
PXR that leads to the release of PXR-bound corepressors,
such as the silencing mediator of retinoic acid and thyroid
hormone receptor (SMRT) and the nuclear receptor corepressor 1
(NCOR1), and the recruitment of its heterodimer partner, the
retinoic X receptor (RXR), and other coactivators, such as steroid
receptor 1114. The PXR/RXR heterodimer directly interactswith speciﬁc promoter sequences of CYP2B6 and CYP3A4
genes and stimulates their transcription115. Additionally, Harmsen
et al.116,117 recently reported that CPA and IFO can also induce
the expression of MDR1 through PXR transactivation.
Although MDR1 represents one of the major mechanisms
associated with the multidrug resistant phenotype in response
to many chemotherapeutics, CPA, IFO, and their proactive
metabolites 4-OH-CPA and 4-OH-IFO, are not typical sub-
strates of MDR134; thus, this induction may not directly affect
the intracellular levels of these oxazaphosphorines and their
active metabolites.
In addition to drug-induced activation, genetic polymorph-
isms of PXR may also affect the metabolism and pharmaco-
kinetics of CPA and IFO in different patients. The presence of
PXR variants was investigated by Hustert et al., in two
Caucasian and African ethnic groups118; three PXR protein
variants (V140M, D163G, and A370T) were identiﬁed to be
functionally associated with altered basal and/or induced
transactivation of CYP3A promoter reporter genes. In a
separate study, Lim et al.119 reported that a Q158K variant
of PXR, found in Chinese population, impairs drug-mediated
induction of CYP3A4 by altering ligand-dependent PXR
interaction with the steroid receptor coactivator-1. Although
autoinduction of CYP3A4 by CPA and IFO was not directly
investigated in these two studies, CPA and IFO are known
activators of PXR, and inducers of CYP3A4 that enhance
their own metabolism and clearance. Thus, these naturally
occurring PXR genetic variants may play a role in the
observed interindividual variability of CYP3A4 expression
and therefore, inﬂuence the varied bioactivation of chemother-
apeutic prodrugs including CPA and IFO.3.2. Constitutive androstane receptor (CAR)
The constitutive androstane receptor, also denoted as the
constitutively activated receptor (CAR; NR1I3), is the closest
relative of PXR in the nuclear receptor superfamily and they
share a panel of overlapping target genes, including a number
of Phase I and II drug-metabolizing enzymes, as well as drug
transporters that are involved in the metabolism and clearance
of the oxazaphosphorines45,97. PXR and CAR also share
many xenobiotic activators, such as the sedative phenobarbi-
tal, the anti-malaria artemisinin, the synthetic opioid metha-
done, as well as the oxazaphosphorine CPA but not
IFO120–124. As such, the extensive cross-talk between PXR
and CAR may form a compensatory biological safety net that
ensures comprehensive protection against various exogenous
and endogenous chemicals. On the other hand, CAR also
holds several unique features that separate itself from PXR
and many other nuclear receptors. First, in line with its
designated name, CAR is constitutively activated and sponta-
neously localized in the nucleus of nearly all immortalized cell
lines independent of chemical stimulation100,110,125. Secondly,
unlike activation of PXR that is prototypically ligand-depen-
dent, CAR could be transactivated by either direct binding to
ligands such as the human CAR selective agonist 6-(4-
chlorophenyl)imidazo-[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-
dichlorobenzyl) oxime (CITCO) or ligand-independent indirect
mechanisms such as the prototypical CYP2B inducer, pheno-
barbital126,127. In fact, the majority of CAR activators identiﬁed
thus far are actually phenobarbital-type of indirect activators
Figure 2 Schematic illustration of cross-talk between PXR and
CAR in the regulation of CYP2B6 and CYP3A4 genes. Activation
of human CAR preferentially induces the expression of CYP2B6
over CYP3A4, while activation of human PXR increases the
expression of both CYP genes with little discrimination. IFO is a
selective activator of human PXR, while CPA can activate both
receptors (modiﬁed from Faucette et al.142).
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from the situation in immortalized cells, CAR is predomi-
nantly localized in the cytoplasm of hepatocytes cultured
in vitro or in the liver in vivo without activation and only
translocates to the nucleus upon chemical stimulation126,128.
Together, these features of CAR make the identiﬁcation of its
activators more challenging, particularly towards a high-
throughput format in vitro. As a result, only a limited number
of CAR activators thus far have been reported, in comparison to
the numerous drugs and environmental toxicants documented as
agonistic ligands of PXR.
Recent studies from our laboratory have shown that CPA but
not IFO is a phenobarbital-like activator of CAR. Treatment of
human primary hepatocytes at clinically relevant concentration
of CPA but not IFO resulted in signiﬁcant nuclear accumulation
of adenovirus-expressing enhanced yellow ﬂuorescent protein-
tagged human CAR120. Supported by additional in vitro data,
it appears that while CPA can activate both PXR and CAR,
IFO primarily transactivates PXR. Assuming this selective auto-
induction also occurs in vivo, these ﬁndings may potentially be of
clinical importance where drug-mediated manipulation of hCAR
activity could alter the autoinduction and pharmacokinetics of
selective oxazaphosphorines.
Similar to that of PXR, accumulating evidence suggests that
both polymorphism and alternative splicing of human CAR
play an important role in the modulation of its target gene
expression129–131. To date, approximately 30 single nucleotide
polymorphisms (SNPs) of the human CAR gene have been
identiﬁed, residing in the 50-ﬂanking regulatory regions, cod-
ing exons, and non-coding introns132. Functional analysis of
four SNPs, localized in the ligand binding domain of CAR,
(His246Arg, Leu308Pro, Asn323Ser, and Val133Gly) revealed
that His246Arg is associated with decreased CAR activation
by CITCO, while Leu308Pro affect basal but not chemically
stimulated CAR activation in cell-based reporter assays131,132.
Recently, a number of naturally occurring alternative splicing
variants of human CAR have been identiﬁed133–135. Func-
tional characterization of these spliced CAR transcripts
revealed that some are associated with altered expression,
cellular localization, and chemical response of the recep-
tor136–139. For instance, unlike its constitutively active refer-
ence form, a splicing variant of human CAR, termed hCAR3,
which contains an insertion of ﬁve amino acids (ALPYT) in
the ligand-binding domain, exhibits low basal but xenobiotic-
inducible activities in immortalized cell lines136,140. Another
splicing variant hCAR2 with an insertion of four amino acids
(SPTV) in a different region of the ligand-binding domain
displays unique proﬁle of xenobiotic-mediated activation that
differs from the reference human CAR141. Together, these
genetic variations of human CAR may differentially affect the
basal and inductive expression of many drug-metabolizing
enzymes that eventually inﬂuence the disposition of CPA and
IFO in clinical practice.
Notably, both human CAR and PXR also exhibit signiﬁ-
cant species-speciﬁc differences in comparison with their
rodent counterparts100,125. In the context of ‘‘cross-talk’’
between these two receptors, while most data imply symme-
trical cross-regulation of their target genes by rodent PXR and
CAR, studies in our lab revealed that human CAR but not
PXR asymmetrically cross-regulate the inductive expression
of CYP2B6 and CYP3A4, in that human CAR exhibits
preferential induction of CYP2B6 over CYP3A4, while humanPXR mediates the expression of both genes with little
discrimination140,142 (Fig. 2). Given that CPA undergoes 4-
hydroxylation to a therapeutically active metabolite primarily
by CYP2B6 and N-dechloroethylation to a non-therapeutic
neurotoxic metabolite by CYP3A4, the preference of hCAR
for CYP2B6 over CYP3A4 may have clinical relevance in
developing novel therapeutic regimens. Concurrent adminis-
tration of CPA with a selective hCAR activator may facilitate
the enhanced production of its beneﬁcial metabolite without
simultaneously increasing formation of its toxic metabolite.3.3. Aryl hydrocarbon receptor (AhR)
Functioning as another xenosensor dictating the inductive
expression of many drug-metabolizing enzymes, AhR is
actually classiﬁed into the basic helix–loop–helix protein of
the PER-ARNT-SIM (PAS) family not to the nuclear receptor
superfamily143. Nevertheless, AhR shares a number of com-
parable characteristics with CAR and PXR, which are
important in modulating the toxicity and biological functions
of many environmental aromatic hydrocarbons and clinically
used drugs144–146. Upon activation, ligand-bound AhR dis-
sociates with its cytoplasmic chaperon partners and translo-
cates to the nucleus. There, it forms a heterodimer with the
aryl hydrocarbon nuclear translocator and stimulates the
expression of its target genes146,147. Along with the ever
growing list of AhR activators, transactivation of AhR is
associated with altered expression of many genes including but
not limited to CYP1A1, CYP1A2, CYP1B1, UGT1As, GST,
ADH, ALDH3A1, and BCRP148–150.
Although AhR-modulated CYP and UGT1A enzymes, and
efﬂux transporter BCRP only have moderate effects on the
bioactivation and clearance of CPA and IFO, other AhR
target genes such as ADH and ALDH3A1, are proved
enzymes that play critical roles in the detoxiﬁcation of these
two oxazaphosphorines (Fig. 1). To date, a number of studies
have shown that the therapeutic outcomes of CPA- and IFO-
based chemotherapy are inversely related to the intracellular
levels of ALDH1A1 and ALDH3A1.The proactive metabo-
lites of CPA and IFO were oxidized by these enzymes to form
the nontoxic 4-keto- and carboxyl-byproducts in competition
with generation of the therapeutically active alkylating mustards
by b-elimination75,151,152. Indeed, cancer cells with higher expres-
sion of ALDH, such as the breast cancer stem-like cells,
demonstrate increased resistance to chemotherapy153. In addition
Oxazaphosphorine bioactivation and detoxiﬁcation 113to chemical-stimulated induction, these ALDH enzymes demon-
strate tissue speciﬁc distribution and developmental changes, and
are also over-expressed in certain types of cancer cells154,155.
Thereby, manipulating tissue-speciﬁc expression of ALDH may
alter the cellular sensitivity to oxazaphosphorines. Notably,
recent studies revealed that other than the prevailing mechanisms
of AhR activation stimulated by exogenous ligands, elevation of
intracellular second messenger cAMP could also lead to the
nuclear translocation of AhR156. Nevertheless, cAMP-mediated
translocation of AhR acts as a repressor in lieu of an activator of
AhR, which leads to repression of AhR target genes including
ALDH156,157. As such, drugs and endogenous signaling mole-
cules differentially modulating the function of AhR may affect
the expression of ALDH enzymes one way or the other and
eventually inﬂuence the clinical responses to CPA- and IFO-
containing regimens.4. Concluding remarks
The oxazaphosphorines CPA and IFO represent the most widely
used chemotherapeutic alkylating agents with a history of clinical
application for more than 50 years. To date, extensive studies
have elucidated the general pharmacology, metabolism, pharma-
cokinetics and cytotoxicity of these oxazaphosphorines. How-
ever, because of the increased polypharmacy in general and in
oxazaphosphorine-based chemotherapy in particular, drug–drug
interactions associated with CPA and IFO multidrug regimens
have become rising concerns in clinical practice. Accumulating
evidence thus far established clearly that hepatic CYP2B6 and
CYP3A4 differentially contribute to the 4-hydroxylation and
N-dechloroethylation of CPA and IFO and many clinical used
drugs and environmental compounds can stimulate the inductive
expression of these two CYP enzymes. Notably, it is only in the
past ten years that marked progress has been achieved in our
understanding of the transcriptional regulation of CYP2B6 and
CYP3A4, which are controlled by a group of transcription
factors, particularly, the CAR and PXR. Importantly, although
activation of PXR induces both CYP3A4 and CYP2B6, selective
activation of CAR leads to preferential induction of CYP2B6
over CYP3A4 in the liver142. This notion might be clinically
attractive in directed modulation of CPA-based chemotherapy,
given the fact that CPA is predominantly bioactivated by
CYP2B6 while deactivated through CYP3A4.
Selective cytotoxicity towards tumor but not normal cells is
the ultimate goal for all chemotherapeutic agents to achieve.
Realizing the speciﬁc role of CYP2B6 in the bioactivation of
CPA, Waxman and colleagues have reported that locally delivery
of adenovirus- or retrovirus-encoding CYP2B expression cassette
into tumor cells resulted in increased intracellular CPA 4-
hydroxylation and cytotoxicity158–160. Thereafter, a number of
studies have demonstrated that such strategy could be successful
in cell cultures in vitro, tumor xenografts in animal, and to a
certain extent in initial clinical trials158,160–162. The current reality,
however, is that clinically used CPA and IFO rely predominantly
on hepatic CYP-mediated biotransformation and the activated
metabolites are transported by erythrocytes to tumors and
normal tissues via blood circulation. Moreover, unlike localized
solid tumors, systemic chemotherapy is necessary for hematopoi-
etic malignancies such as lymphoma and leukemia, in which
CPA continues to be used among the ﬁrst-line R-COUP regimen.
Therefore, understanding the role of xenobiotic receptors in theregulation of key drug-metabolizing enzymes in the liver invol-
ving the bioactivation and deactivation of oxazaphosphorine
agents is of both scientiﬁc signiﬁcance and clinical importance.Acknowledgments
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